Drug Profile
Oteseconazole - Mycovia Pharmaceuticals
Alternative Names: SHR-8008; VIVJOA; VT-1161Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Viamet Pharmaceuticals
- Developer Jiangsu Hengrui Medicine Co.; Mycovia Pharmaceuticals; Viamet Pharmaceuticals
- Class Antifungals; Foot disorder therapies; Pyridines; Small molecules; Tetrazoles
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Vulvovaginal candidiasis
- Phase II Onychomycosis
- Phase I Coccidioidomycosis; Cryptococcosis; Immunocompromised infections; Invasive candidiasis
- Discontinued Tinea pedis
Most Recent Events
- 29 Feb 2024 Phase-I clinical trials in Coccidioidomycosis (unspecified route) Prior to February 2024 (Mycovia Pipeline, February 2024)
- 29 Feb 2024 Phase-I clinical trials in Cryptococcosis (unspecified route) Prior to February 2024 (Mycovia Pipeline, February 2024)
- 29 Feb 2024 Phase-I clinical trials in Invasive candidiasis (unspecified route) Prior to February 2024 (Mycovia Pipeline, February 2024)